AstraZeneca 3Q Results Beat Expectations, JPMorgan Says
J.P. Morgan analysts said AstraZeneca beat expectations on revenue and the bottom line and reiterated its 2026 and 2030 guidance. The analysts expect a positive share reaction.
AstraZeneca's third-quarter results beat expectations at the top and bottom lines and the company reiterated its guidance for 2026 and 2030, which should trigger a positive share reaction, J.P. Morgan's analysts say in a note. "Overall, we expect the strong set of results including the top and bott…